NanoDiagNCD (JTC10 2027) - nowy konkurs w ramach partnerstwa ERA4Health, start w listopadzie 2026 r.
16.10.2026
W dniu 17 listopada 2026 r. partnerstwo ERA4Health uruchamia konkurs na projekty badawcze pt. Nano and advanced technologies for developing Diagnostic and Theranostic tools to improve the detection and the clinical management of non-communicable diseases - NanoDiagNCD
Partnerstwo ERA4Health (Fostering a European Research Area for Health) wspiera badania i innowacje dotyczące zdrowia publicznego w Europie.
W dniu 17 listopada 2026 r. startuje konkurs na projekty badawcze pt. Nano and advanced technologies for developing Diagnostic and Theranostic tools to improve the detection and the clinical management of non-communicable diseases – NanoDiagNCD.
Zakres tematyczny (skrót):
The aim of this call is to support translational research projects that develop application(s) of nanotechnologies, either solely or in combination with Key Enabling Technologies (KETs), to make significant strides in the development of diagnostic and theranostic tools for Non-Communicable Diseases (NCDs). Proposals should focus on developing and/or validating diagnostic and theranostic tools that are grounded in robust scientific evidence. The results obtained from these tools must enable the optimisation of the care continuum. This care continuum includes, among other things, prevention, early disease detection, disease monitoring, treatment guidance, adverse effect and/or risk/benefit assessment.
The proposed research must define and validate performance benchmarks against existing diagnostic approaches to demonstrate added value in terms of sensitivity, specificity, accessibility, affordability, patient comfort, invasiveness and/or safety.
In addition, at any stage of the research and for all applications, translational and adoption requirements for nano-enabled diagnostic and theranostic solutions must be considered. This includes scalability, manufacturability, standardisation, affordability, accessibility, cost-effectiveness, regulatory readiness, interoperability, and integration across different healthcare systems.
In case of the development of theranostic tool(s), the proposed approach must apply a diagnosticfirst principle, where diagnostic must serve the therapeutic choice.
Exclusion:
Proposals where nanotechnology is not central.
Discovery of new biomarkers. However, the development of known biomarkers is allowed such as technological advancements to improve the performance of existing biomarker-based tests, integration of multiple known biomarkers into single platforms, optimization for a different application, etc.
Infectious diseases are excluded but studies on chronic diseases resulting from past infectious diseases are allowed.
W dniu 19 listopada 2026 r. planowane jest spotkanie informacyjne dla potencjalnych uczestników konkursu. Szczegóły wkrótce, prosimy o śledzenie strony programu: https://era4health.eu/.
Zamkniecie naboru wniosków konkursowych jest planowane w dniu 19 stycznia 2027 r. (12.00 CET)
Więcej szczegółów znajduje się w ogłoszeniu wstępnym konkursu NanoDiagNCD (https://era4health.eu/calls/pre_NanoDiagNCD2027.php)
Zachęcamy do skorzystania z naszej Wyszukiwarki Partnerów „PartFinder”, która umożliwia kojarzenie ze sobą podmiotów z sektora nauki i przemysłu z całego Świata. Narzędzie jest oficjalną aplikacją partnerstwa ERA4Health. Wyszukiwarka dostępna pod adresem: https://partfinder.ncbr.gov.pl/